Copenhagen, 6 April 2011 - Zealand Pharma (NASDAQ OMX: ZEAL), a Scandinavian based biopharmaceutical company hosts a capital market day and site visit at its Copenhagen headquarters today from 12:00 to 16:30 CEST.
The Zealand Pharma management team will present a business overview focussing on the company’s strategy and the status of the company’s pipeline of novel peptide drugs, including lixisenatide, a novel GLP-1 drug in late-stage Phase III development for the treatment of Type 2 Diabetes in collaboration with sanofi-aventis. No new material information will be disclosed. The event also features a keynote speech by Dr. Bernard Charbonnel, Chair of the Department of Medicine at the Université de Nantes, on the outlook for diabetes treatment and the impact of GLP-1 and new insulin treatments.
A live webcast and replay of the event can be accessed via the IR section of the company’s website at http://ir.zealandpharma.com/.
The live webcast will begin at 12:00 CEST and finish at 16:30 CEST, with a break from 12:50 to 14:00 CEST for the site visit.
For further information, please contact:
Zealand Pharma
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 8877 3689 or Mobile: +45 5060 3689, hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) Scandinavian based biopharmaceutical company with a mature and growing clinical pipeline of innovative peptide drugs. The company’s lead product candidate is a once-daily GLP-1 in late-stage Phase III development for the treatment of Type 2 Diabetes in collaboration with sanofi-aventis. Zealand Pharma also has several other collaboration and licensing partnerships, including a license agreement with Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of Chemotherapy and Radiotherapy Induced Diarrhoea.
Zealand Pharma has unique expertise in peptide discovery and optimization and in the development of novel peptide drugs with favourable therapeutic attributes. The company targets metabolic (diabetes and obesity), gastrointestinal and cardiovascular diseases, where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. All of Zealand Pharma’s product candidates have been identified through the company’s own drug discovery activities. The company is headquartered in Copenhagen and has approximately 90 employees. For more information please visit www.zealandpharma.com
